(AMPH) Amphastar P - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03209R1032

AMPH: Injectables, Inhalation Products, Intranasal Sprays, Emergency Kits, APIs

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a bio-pharmaceutical company specializing in the development, manufacturing, and distribution of generic and proprietary injectable, inhalation, and intranasal products. With operations in the United States, China, and France, the company focuses on critical care and emergency medicine, offering a diverse portfolio of products that address acute and life-threatening conditions. Its product lineup includes BAQSIMI, a nasal spray for severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for mild asthma symptoms; and Enoxaparin for deep vein thrombosis prevention and treatment. Additionally, Amphastar provides REXTOVY and Naloxone for opioid overdose reversal, Glucagon emergency kits, and Cortrosyn for diagnostic purposes in adrenocortical insufficiency screening.

The company also manufactures Amphadase, a hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly and topical solution for anesthetic use; Phytonadione injection for newborns; emergency syringe products; morphine injection for patient-controlled analgesia; and Lorazepam injection for surgical procedures. Its portfolio further includes Neostigmine methylsulfate for myasthenia gravis treatment; Isoproterenol hydrochloride for heart block episodes; Ganirelix Acetate for premature luteinizing hormone surge inhibition; Vasopressin for blood pressure management; and Regadenoson for myocardial perfusion imaging. Amphastar also distributes recombinant human insulin APIs and porcine insulin API, while developing generic and biosimilar product candidates, including intranasal epinephrine for allergic reactions.

Founded in 1996 and headquartered in Rancho Cucamonga, California, Amphastar has established itself as a key player in the pharmaceutical industry, particularly in injectable and inhalation technologies. The company’s focus on R&D and its extensive product range position it as a reliable supplier of essential medications for critical care and emergency situations.

Ticker Symbol: AMPH
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Pharmaceuticals

Average Volume 20d: 543,608
Last Price: 24.50
SMA 20: 24.17
SMA 50: 26.78
SMA 200: 38.99
ATR: 1.02

Market Cap: 1,136.73M USD
P/E: 7.82
P/E Forward: None
P/B: 1.55
P/S: 1.55
RoE: 21.78

Forecast: Based on the provided data, Amphastar Pharmaceuticals (AMPH) is currently trading at $24.50, slightly above its SMA 20 of $24.17 but below its SMA 50 of $26.78. The stock’s ATR of 1.02 indicates moderate volatility. Fundamentally, the company’s P/E ratio of 7.82 suggests undervaluation compared to industry peers, while its return on equity (RoE) of 21.78 highlights strong profitability. However, the P/S ratio of 1.55 may signal elevated valuations relative to sales. Moving forward, AMPH is likely to experience short-term price consolidation near the SMA 50 resistance level, with potential upside driven by its robust earnings and product pipeline. Investors should monitor technical support at the SMA 20 and fundamental catalysts such as new product approvals or margin expansion.

Additional Sources for AMPH Stock

AMPH Stock Overview

Market Cap in USD 1,164m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2014-06-25

AMPH Stock Ratings

Growth Rating 19.4
Fundamental 89.1
Dividend Rating 0.0
Rel. Strength -39.1
Analysts 3.83/5
Fair Price Momentum 20.31 USD
Fair Price DCF 77.84 USD

AMPH Dividends

No Dividends Paid

AMPH Growth Ratios

Growth Correlation 3m -85.6%
Growth Correlation 12m -60.9%
Growth Correlation 5y 76.5%
CAGR 5y 5.14%
CAGR/Max DD 5y 0.08
Sharpe Ratio 12m -1.08
Alpha -48.78
Beta 0.462
Volatility 48.49%
Current Volume 751.6k
Average Volume 20d 543.6k
What is the price of AMPH stocks?
As of May 09, 2025, the stock is trading at USD 24.65 with a total of 751,566 shares traded.
Over the past week, the price has changed by +3.22%, over one month by +3.79%, over three months by -23.47% and over the past year by -41.60%.
Is Amphastar P a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Amphastar P (NASDAQ:AMPH) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 89.07 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMPH as of May 2025 is 20.31. This means that AMPH is currently overvalued and has a potential downside of -17.61%.
Is AMPH a buy, sell or hold?
Amphastar P has received a consensus analysts rating of 3.83. Therefor, it is recommend to buy AMPH.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0
What are the forecast for AMPH stock price target?
According to ValueRays Forecast Model, AMPH Amphastar P will be worth about 21.9 in May 2026. The stock is currently trading at 24.65. This means that the stock has a potential downside of -11.03%.
Issuer Forecast Upside
Wallstreet Target Price 38 54.2%
Analysts Target Price 38 54.2%
ValueRay Target Price 21.9 -11%